Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P. Goetz(Mayo Clinic), S. Johnston(Royal Marsden NHS Foundation Trust), Guido Van Hal(University of Antwerp), M. Toi(Tokyo Metropolitan Komagome Hospital), Olivier Trédan(Centre Léon Bérard), Antonio Llombart‐Cussac(MedSIR (Spain)), Joyce O’Shaughnessy(Baylor University Medical Center), Hiroaki Iwata(Gifu University), Xavier Pivot(Levi Strauss (United States)), Ashwin Shahir(Eli Lilly (United States)), Shyr‐Chyr Chen(Chang Gung University), Jens Huober(University of St.Gallen), Sara A. Hurvitz(University of Washington), Mario Campone(Institut de Cancérologie de l'Ouest), I.H. Park(National Cancer Center), Abhijoy Saha(Eli Lilly (United States)), Valérie André(Eli Lilly (United States)), S.M. Tolaney(Dana-Farber Cancer Institute), Luis Manual Manso(Hospital Universitario 12 De Octubre), Shani Paluch–Shimon(Hebrew University of Jerusalem), J. Sohn(Yonsei University), Orit Freedman(Regional Municipality of Durham)
Cited by 204
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k